Even at this early stage of development, it is clear that imaging hyperpolarized 13C-enriched molecules and their metabolic products offers a new approach to studying physiology and disease in the heart. The technology will be practical in humans and for this reason we consider whether a role in clinical decision-making should motivate further development. The range of interventions available to treat coronary and valvular heart disease is already extensive, and new options are imminent. Yet the proper management of patients with left ventricular dysfunction can be challenging because the mechanism of reduced function may be unclear and the ability of the ventricle to respond to therapy may be difficult to predict. Pyruvate is a promising early target for development as a diagnostic agent to because it lies at a critical branch point in cardiac biochemistry. The relative rate of metabolism of hyperpolarized pyruvate to CO2 compared to lactate may prove to be a useful indicator of preserved mitochondrial function and therefore provide a specific signal of viable myocardium. Other molecules including physiological substrates as well as nonphysiological molecules provide additional information. Once suitable technology becomes available it is likely that clinical research will progress quickly. The ability to directly monitor specific metabolic pathways may improve our ability to select patients who will benefit from interventions, pharmacologic or otherwise.